Advisory panel: expand hepatitis therapy to HIV/AIDS patients.
D000998:Antiviral Agents / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use*; D014481:United States
D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons